Affiliation:
1. Department of Pediatrics Xinqiao Hospital, Second Affiliated Hospital of Army Medical University Chongqing 400037 China
2. National and Regional United Engineering Lab of Tissue Engineering, Department of Orthopedics Southwest Hospital, Army Medical University Chongqing 400037 China
3. Department of Pediatrics Xinqiao Hospital, Second Affiliated Hospital of Army Medical University 400037 Chongqing China
Abstract
AbstractErythropoietin (EPO) is an excellent neuroprotective molecule that decreases the extent of injury caused by various pathologies of the brain, such as Alzheimer's disease, Parkinson's disease, and stroke. However, due to the low permeability of the blood‒brain barrier (BBB), a high dose or even an overdose of EPO injections is often administered to achieve a sufficient EPO concentration in the brain. This often leads to many serious adverse reactions. Several studies have presented promising strategies for overcoming the BBB to deliver EPO. These methods include the formation of EPO modified by receptor‐mediated transcytosis targeting fusion proteins, cell‐penetrating peptides, and nanomaterials. In this review, the clinical progress of modified brain‐targeting drug delivery systems of EPO is summarized to provide a scientific basis and new information on the application of EPO in treating diseases of the central nervous system. Here, the production, pharmacological effects, and mechanism of action of the modified EPO, as well as the limiting factors and countermeasures are discussed.
Funder
National Natural Science Foundation of China
Subject
Pharmacology (medical),Biochemistry (medical),Genetics (clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)